Barclays PLC Grows Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Barclays PLC grew its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 369.2% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 365,046 shares of the company's stock after buying an additional 287,243 shares during the period. Barclays PLC owned 0.81% of Apogee Therapeutics worth $21,443,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Point72 DIFC Ltd purchased a new position in Apogee Therapeutics in the 2nd quarter valued at $660,000. Point72 Asset Management L.P. boosted its holdings in shares of Apogee Therapeutics by 162.7% in the third quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company's stock valued at $41,545,000 after acquiring an additional 438,036 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Apogee Therapeutics during the second quarter worth about $706,000. Victory Capital Management Inc. raised its holdings in Apogee Therapeutics by 56.8% during the second quarter. Victory Capital Management Inc. now owns 156,266 shares of the company's stock worth $6,149,000 after purchasing an additional 56,607 shares in the last quarter. Finally, Waypoint Capital Advisors LLC purchased a new position in Apogee Therapeutics during the third quarter worth about $36,835,000. Institutional investors and hedge funds own 79.04% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wedbush lifted their price objective on Apogee Therapeutics from $87.00 to $90.00 and gave the company an "outperform" rating in a report on Monday, December 2nd. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating and a $89.00 price target on the stock. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a "buy" rating and a $89.00 price objective on the stock. Finally, Guggenheim reissued a "buy" rating on shares of Apogee Therapeutics in a report on Thursday. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics has an average rating of "Buy" and a consensus price target of $83.88.

Apogee Therapeutics Stock Performance

APGE stock traded up $0.18 during midday trading on Friday, hitting $44.50. 692,234 shares of the stock were exchanged, compared to its average volume of 504,108. The stock's 50-day moving average price is $51.43 and its 200-day moving average price is $48.30. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -18.39 and a beta of 2.30. Apogee Therapeutics, Inc. has a fifty-two week low of $20.78 and a fifty-two week high of $72.29.

Insider Transactions at Apogee Therapeutics

In other news, CEO Michael Thomas Henderson sold 15,000 shares of the company's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $59.22, for a total value of $888,300.00. Following the sale, the chief executive officer now directly owns 1,339,487 shares in the company, valued at $79,324,420.14. This represents a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carl Dambkowski sold 4,540 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total value of $221,370.40. Following the sale, the insider now directly owns 258,073 shares in the company, valued at approximately $12,583,639.48. The trade was a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 94,535 shares of company stock valued at $5,133,635 in the last 90 days. 36.10% of the stock is currently owned by insiders.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.